Scottish Medicines Consortium Recommends Boehringer’s Trajenta
The Scottish Medicines Consortium (SMC) have issued final advice recommending the approval of Boehringer Ingelheim’s Trajenta with insulin to treat adults with type 2 diabetes to improve glycaemic control.
The recommendation follows a Health Technology Appraisal accepting Trajenta (linagliptin) for treatment in combination with insulin with or without metformin, when insulin alone, with diet and exercise, does not provide adequate glycaemic control.
Trajenta has been studied in randomised controlled clinical trials that have included over 5,000 patients with type 2 diabetes mellitus. Within the trials, treatment with Trajenta provided significant reductions in HbA1c and compared with placebo, it improved glycaemic control in these adults who had inadequate glycaemic control on an insulin-containing regimen.
Previously, the SMC has granted regulatory approval to linagliptin for restricted use as monotherapy in combination with metformin, and in combination with a sulphonylurea and metformin. The recommendation has now been extended to include the use of linagliptin in combination with insulin.
Charles De Wet, Boehringer Ingelheim’s UK medical director commented: “We are very pleased that the SMC has now extended their recommendation for linagliptin in combination with insulin for Type 2 diabetes patients in Scotland.”